“SYSTEMATIC REVIEW OF THE COST-EFFECTIVENESS OF ABEMACICLIB IN THE TREATMENT OF HR+/HER2− ADVANCED OR METASTATIC BREAST CANCER ”, YHCĐ, vol. 67, no. 10, Nov. 2026, doi: 10.52163/yhc.v67i10.6967.